Japanese / English

The First International Conference

Drug Discovery, Development and Optimization of ADME Propertis


The date and place:

Date: September 25-26, 2013


            Tokyo, Japan  Access


Registration Fee: Free


Registration period: June 26(Wed) - 
September 24(Tue)
Registration can be made online.


 [This meeting is a part of the RIKEN Symposium series.] 



Academia Originated Drug Discovery and Development

Wednesday, 25



Toshio Goto

RIKEN Program for Drug Discovery and Medical Technology Platform, Program Director

RIKEN Program for Drug Discovery and Medical Technology Platform


Yasuyoshi Watanabe

RIKEN Center for Life Science Technologies, Center Directer

PET Molecular Imαging for Drug Development


Michiaki Kubo

RIKEN Center for Integrative Medical Sciedces,Deputy Director

From Gene Discovery to Personalized Medicine


Yoshihide Hayashizaki

RIKEN Preventive Medicine & Diagnosis Innovation Program (PMI) , Program Director

The Exploration of Biomarkers and Preventive Medicine


Tetsuo Nagano

Open Innovation Center for Drug Discovery,The University of Tokyo, Professor

Difference between Academia and Industry in Drug Discovery



Hideo Utsumi

Phαrmαceuticals αnd Medicαl devices Agency,Executive Director, Director General of the Office of Review Innovation

The Science Board in PMDA


Jin-ding Huang

National Cheng Kung University,Professor,Taiwan

Building Trust and Cooperation among Academics,Industry,and Health Authorities


Kicking around Draft Guidance on Drug Interaction Studies

Supported by The Japanese Society for the Study of Xenobiotics (JSSX)

Thursday, 26



Yasuo Ohno

National lnstitute of Health Sciences,Visiting scientists

Revislon of Japanese Guidance on Drug Interaction Studies and its Basic Principle 


Hiroshi Suzuki

The University of Tokyo Hospital, Faculty of Medicine, the University of Tokyo, Professor

Major Points of the Revision of Japanese Guidance on Drug Interaction Studies 


Kiyomi Ito

Faculty of Pharmacy, Musashino University, Professor

Evaluation of Drug Interactions Involving Drug Metabolism 


Kazuya Maeda

Graduate school of Pharmaceutical Sciences, The University of Tokyo, Lecturer

Basic Concepts and Key Points of the Evaluation of Transporter-Mediated Drug Interactions 


Akihiro Hisaka

22nd Century Medical and Research Center, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Associate Professor

Science Based Management of Drug Interactions 


Hot Topics of Pharmacokinetic Study in New Drug Discovery and Development 

Supported by Forum for Pharmaceutical Technology Innovation

Thursday, 26


Seiji Miyauchi

Faculty of Pharmaceutical Sciences, Laboratory of Pharmacokinetics Toho University, Professor

Na+-Dependent Opioid Peptide Transporter as a Molecular Target for Drug Development 


Hiroyuki Kusuhara

Graduate School of Pharmaceutical Sciences, The University of Tokyo, Professor

Quantitative Evaluation of the Impact of P-gp and Bcrp at the BBB on the Unbound Concentrations of Drugs in the Brain 


Ikumi Tamai 

Graduate School of Medical Sciences, Kanazawa University, Professor

Involvement of OATP2B1 in Drug Absorption and Interaction 

Ryota Kikuchi 

Abb Vie Inc. 

What, When, and Why of Drug Transporters: Strategies Across Discovery and Development 

Jasminder Sahi 

GSK Shanghai  

Discovery and Development of CNS Drug; Viewpoint from ADME Scientist 

【 Contact Us 


The First International Conference of Sugiyama Laboratory

RIKEN Research Center for Innovation

1-6 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan

PHONE: +81- 45-506-1816  Fax: +81-45-506-1800

MAIL: info[at]riken-sugiyama.jp